Apogee to Reveal Phase 2 Zumilokibart AD Data
SAN FRANCISCO and BOSTON, May 26, 2026 Apogee Therapeutics announced it will report Part B 16-week clinical data from...
atopic dermatitis
Advertisement
Elanco Launches Befrena for Canine Allergy and Itch Relief
Indianapolis, Indiana, USA – May 18, 2026 Elanco Animal Health Incorporated announced the phased U.S. launch of Befrena™ (tirnovetmab),...
Castle Biosciences Wins 2026 Genomics Innovation Award
FRIENDSWOOD, Texas, May 12, 2026 Castle Biosciences announced that its AdvanceAD-Tx™ gene expression profiling test received the prestigious 2026...
Alkermes Reports Strong Phase 3 LUMRYZ Trial Data
DUBLIN, Ireland, May 12, 2026 Alkermes announced positive topline results from the pivotal REVITALYZ Phase 3 clinical trial evaluating...
TRexBio Reports New TRB-061 Data for Atopic Dermatitis
SOUTH SAN FRANCISCO, Calif., May 7, 2026 TRexBio announced new late-breaking translational and preclinical data supporting TNFR2 agonism as...
Advertisements
Incyte Opzelura Shows Durable Atopic Dermatitis Benefit
WILMINGTON, Del., May 7, 2026 Incyte announced positive 24-week long-term results from the Phase 3 TRuE-AD4 clinical trial evaluating...
Bambusa Therapeutics Completes BBT001 Trial Enrollment
BOSTON, MASSACHUSETTS, April 30, 2026 Bambusa Therapeutics has announced the successful completion of patient enrollment in its Phase 1b/2a...
TRexBio Advances TRB-061 Phase 1b Trial for Atopic Dermatitis
SOUTH SAN FRANCISCO, April 29, 2026 TRexBio, Inc. has announced that the first patient has been dosed in the...
Organon VTAMA Cream Gains Strong AAD Guideline Support
Jersey City, New Jersey, U.S. | April 15, 2026 Organon has announced that its VTAMA® (tapinarof) cream, 1% has...
Rezpegaldesleukin Shows Strong Phase 2b Results in AD
San Francisco, USA | March 28, 2026 Phase 2b Data Demonstrates Strong Clinical Efficacy Nektar Therapeutics has announced compelling...
Advertisement
